July 31, 2024 03:48 AM EDTUpdated August 1, 03:03 PM
People
R&D

Fi­bro­Gen to shrink US work­force by 75% fol­low­ing more late-stage fails

Kyle LaHucik

Senior Reporter

Fi­bro­Gen’s two-year rough streak con­tin­ued on Tues­day as the San Fran­cis­co-based biotech said its pan­cre­at­ic can­cer drug pam­revlum­ab failed two late …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times